Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiomyopathy and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRKAG2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRKAG2 WT / Mutant Protein (e.g., N488I, R302Q). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Full-length and CBS domain truncations available. | View PRKAG2 Products |
| Disease Mutants | Cardiomyopathy variants (R302Q, N488I) for Wolff-Parkinson-White syndrome modeling. Sequence Verified. | View PRKAG2 Products |
| Gene Delivery | PRKAG2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. | View PRKAG2 Products |
| Benchmark Ab | Anti-PRKAG2 Control Antibody. Recombinant positive control for western blot and target engagement assays. | View PRKAG2 Products |
| Validator | PRKAG2 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. HPLC purified. | View PRKAG2 Products |
| Related Target: PRKAA2 | AMPK α2 Catalytic Subunit. Heterotrimeric complex assembly partner. | View PRKAA2 Products |
| Related Target: PRKAB2 | AMPK β2 Scaffolding Subunit. Essential for complete AMPK assembly. | View PRKAB2 Products |
| Related Target: PRKAG1 | AMPK γ1 Subunit. Isoform specificity testing (γ1 vs γ2 selectivity profiling). | View PRKAG1 Products |
| Related Target: PRKAG3 | AMPK γ3 Subunit. Muscle-specific isoform for tissue selectivity assays. | View PRKAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (γ1 vs γ2 vs γ3) | Human PRKAG1, PRKAG2, PRKAG3 recombinant proteins with matched CBS domain boundaries (>95% purity) for direct comparison binding assays. |
| Heterotrimeric Complex Assembly | PRKAG2 + PRKAB2 + PRKAA2 co-expression compatible; verified protein-protein interaction motifs. |
| Cardiomyopathy Mutant Screening | Rare disease mutants (R302Q, N488I) available with wild-type controls; Sequence Verified. |
| Nucleotide Binding Integrity | CBS domain proteins verified for AMP/ADP/ATP binding competence (theoretical binding sites intact). |
| Lack of Reliable Pathway Controls | Recombinant positive control antibodies included for rigorous validation without background noise. |
| Target Validation False Positives | Sequence-optimized siRNA sets included for precise specificity and genetic knockdown checks. |
Live PRKAG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Cardiomyopathy Research
- AMPK Activator Development
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PRKAG2-targeted therapeutics is evolving rapidly, driven by the profound link between PRKAG2 mutations and familial hypertrophic cardiomyopathy (HCM) with glycogen storage anomalies. As researchers shift focus from broad AMPK activators to highly specific, isoform-selective small molecules and targeted gene therapies, the primary R&D bottleneck has become the precise evaluation of the Gamma-2 subunit in complex with Alpha and Beta subunits. While first-generation direct activators faced safety challenges (cardiac hypertrophy risks), the current wave of R&D focuses on tissue-selective allosteric activators and allele-specific modulation for cardiomyopathy. The cardiac-specific expression of PRKAG2 presents both a therapeutic opportunity for heart failure and a safety liability for metabolic drugs, necessitating rigorous isoform selectivity screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Activator/Allosteric) | Pfizer, Betta Pharma, Bayer, Merck | Metabolic Disorders, Heart Failure, Cardiomyopathy | Selectivity Assay (Need High-Purity WT vs Isoform Proteins); Mutant Binding Assay (Need N488I/R302Q Mutant Recombinant Proteins) |
| Gene Therapy / siRNA | Academic Spin-offs, Academic Consortia | Familial HCM (PRKAG2 Syndrome) | Expression Validation (Need specific PRKAG2 siRNA & Lentivirus); Disease Mutant Validation (R302Q, N488I vs WT comparison) |
| Indirect/Allosteric Activators | AstraZeneca, Merck, Lilly, Novo Nordisk | Type 2 Diabetes, NASH, Metabolic Syndrome | Heterotrimer Assembly (Full γ2 + α2 + β2 complex reagents); Isoform Selectivity Panel (γ1/γ2/γ3 proteins needed for cross-screening) |
| Small Molecule Inhibitors (Oncology) | Oncology-focused biotechs | Cancer (metabolic reprogramming) | Activity Assay Ready (Catalytic + γ2 complex for ATP competition) |